Live News • Jul 04
Court Upholds Infineon GaN Product Ban After Patent Win for InnoScience On May 27, 2026, the Suzhou Intermediate People’s Court ruled that Infineon Technologies infringed two of InnoScience (Suzhou) Technology Holding’s GaN invention patents and ordered Infineon to stop sales and importation of the infringing products in mainland China, with the Supreme People’s Court later rejecting Infineon’s reconsideration request and upholding the injunction.
The ruling led to Infineon removing the court-enjoined GaN products from its booth at electronica China 2026. This reinforced InnoScience’s patent rights in GaN power devices within the Chinese market and may affect how competitors market similar products at domestic trade shows.
InnoScience’s shares trade at HK$60.65, with the stock down 19.0% year to date, so this legal outcome lands against a weaker recent share price backdrop.
The court decisions clarify InnoScience’s patent protection around key GaN products in China, but investors still have to weigh how effectively the company can convert this stronger legal footing into sustainable product demand and margins while litigation and enforcement efforts continue. Announcement • Jun 19
Innoscience Announces Munich Regional Court Rules Current Products Fall Outside Scope of Infineon Patents Innoscience announced that the Munich Regional Court has just issued a pair of rulings, from which it could be confirmed that Innoscience's currently marketed gallium nitride ("GaN") power device products fall outside the scope of Infineon's asserted German patents and may be commercialized in Germany without restriction. These rulings are fully consistent with the final determination issued last month by the U.S. International Trade Commission ("ITC"), which found that Innoscience's current products do not infringe Infineon's asserted U.S. patent relating to packaging design (U.S. Patent No. 9,899,481). The Munich case concerns the German counterparts of that same patent family. In line with the ITC's findings, the Munich Court found infringement only with respect to a limited set of legacy products—certain packaged 650–700V transistors—that had already been discontinued. Therefore, any injunction granted would not apply to Innoscience's current product portfolio. As a result, there is no impact on Innoscience's ongoing operations or its customers' use of its products in Germany. The decisions mark another significant milestone in Innoscience's string of favorable outcomes across major jurisdictions. They follow the company's recent success in China, where it secured an injunction and damages award against Infineon, as well as its decisive victory at the ITC in the United States last month. Together, these rulings reaffirm the legality of Innoscience's current product portfolio and its ability to operate freely in key global markets. While proceedings in Germany remain ongoing, including Innoscience's invalidity challenges to the asserted German patent, the growing body of decisions across China, the United States, and Germany underscores that the global litigation campaign initiated by Infineon has not altered the competitive position of Innoscience's core products. To the contrary, independent judicial findings across multiple jurisdictions have consistently validated the robustness of Innoscience's technology and reinforced market confidence in the company's product compliance and innovation capabilities. Innoscience remains committed to advancing its technology leadership and expanding its global footprint, delivering cutting-edge GaN solutions to customers worldwide in a fair and competitive marketplace. New Risk • May 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. 
